Influence of inflammatory cells and serum on the performance of implantable glucose sensors

Gerritsen, M.; Jansen, J. A.; Kros, A.; Vriezema, D. M.; Sommerdijk, Nico A. J. M.; Nolte, R.J.M.; Lutterman, J.A.; Hövell, S. W. F. M. Van; Gaag, A. Van der

doi:10.1002/1097-4636(200101)54:1<69::aid-jbm8>3.3.co;2-h

Cited by 34 publications

(55 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was supported by similar results by other researchers [19][20][21] . Some of the risks of these implants are tissue injury and initiation of foreign body reactions due to long time interaction between the device and body.…”

Section: Why Non-invasive Technique?supporting

confidence: 91%

“…Some of the risks of these implants are tissue injury and initiation of foreign body reactions due to long time interaction between the device and body. Apart from these factors, the glucose diffusion to the sensor is also affected by absorption of nonspecific protein from the tissue fluid [19][20][21] . Hence the challenge still remains for stability and sensitivity along with biocompatibility for these invasive techniques [14] .…”

Section: Why Non-invasive Technique?mentioning

confidence: 99%

See 1 more Smart Citation

Non-invasive method to detect the changes of glucose concentration in whole blood using photometric technique

Rajan

Towe

2014

2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

View full text Add to dashboard Cite

A noninvasive optical method is developed to monitor rapid changes in blood glucose levels in diabetic patients. The system depends on an optical cell built with a LED that emits light of wavelength 535nm that is a peak absorbance of hemoglobin. As the glucose concentration in the blood decreases, its osmolarity also decreases and the RBCs swell and decrease the path length absorption coefficient.Decreasing absorption coefficient increases the transmission of light through the whole blood.The system was tested with a constructed optical cell that held whole blood

show abstract

Section: Why Non-invasive Technique?supporting

confidence: 91%

Section: Why Non-invasive Technique?mentioning

confidence: 99%

Non-invasive method to detect the changes of glucose concentration in whole blood using photometric technique

Rajan

Towe

2014

2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society

View full text Add to dashboard Cite

show abstract

“…Bleeding has been previously described as interfering with proper subcutaneous sensor function (9). Other sensors showed considerable drift in sensor signal although the reason for the drift is not obvious, possibly reflecting occult hemorrhage/thrombus formation, tissue protein adsorption, localized accumulation of inflammatory cells, or fibrous encapsulation at the sensor-tissue interface (7,16,17). Sensor drift into the hypoglycemic range was noted in several patients, but these "occult" hypoglycemic episodes were not corroborated by concurrent blood glucose measurements (data not shown).…”

Section: Discussionmentioning

confidence: 99%

Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor

Boyne

Silver²,

Kaplan³

et al. 2003

Diabetes

361

275

View full text Add to dashboard Cite

The objective of this study was to use a subcutaneous continuous glucose sensor to determine time differences in the dynamics of blood glucose and interstitial glucose. A total of 14 patients with type 1 diabetes each had two sensors (Medtronic/MiniMed CGMS) placed subcutaneously in the abdomen, acquiring data every 5 min. Blood glucose was sampled every 5 min for 8 h, and two liquid meals were given. A smoothing algorithm was applied to the blood glucose and interstitial glucose curves. The first derivatives of the glucose traces defined and quantified the timing of rises, peaks, falls, and nadirs. Altogether, 24 datasets were used for the analysis of time differences between interstitial and blood glucose and between sensors in each patient. Time differences between blood and interstitial glucose ranged from 4 to 10 min, with the interstitial glucose lagging behind blood glucose in 81% of cases (95% CIs 72.5 and 89.5%). The mean (؎SD) difference between the two sensors in each patient was 6.7 ؎ 5.1 min, representing random variation in sensor response. In conclusion, there is a time lag of interstitial glucose behind blood glucose, regardless of whether glycemia is rising or falling, but intersensor variability is considerable in this sensor system. Comparisons of interstitial and blood glucose kinetics must take statistical account of variability between sensors. Diabetes 52:2790 -2794, 2003

show abstract

“…A similar functional loss of glucose sensors has been reported by numerous researchers. [85][86][87][88][89] Surgical implantation of glucose sensors is accompanied by tissue injury, and the surface of the device interacts with the body for a long time, both initiating and maintaining the foreign body reaction. Most functional loss of biosensor activity is assumed to be caused by histological changes that occur in the tissue surrounding the implant (specifically, inflammatory reaction and/or fibrous encapsulation).…”

mentioning

confidence: 99%

“…Most functional loss of biosensor activity is assumed to be caused by histological changes that occur in the tissue surrounding the implant (specifically, inflammatory reaction and/or fibrous encapsulation). There are many implications in the literature that glucose diffusion is influenced negatively by nonspecific protein absorption from the tissue fluid to the sensor surface, 85,90 and the fibrous capsule that forms around implanted sensors restricts the transport of even low molecular weight analytes such as glucose to the sensor surface. [91][92][93][94][95][96][97][98] Consequently, maintaining glucose sensor function in an in vivo environment remains a key challenge.…”

mentioning

confidence: 99%

A Review of the Biocompatibility of Implantable Devices: Current Challenges to Overcome Foreign Body Response

Onuki

Bhardwaj

Papadimitrakopoulos

et al. 2008

J Diabetes Sci Technol

344

282

View full text Add to dashboard Cite

In recent years, a variety of devices (drug-eluting stents, artificial organs, biosensors, catheters, scaffolds for tissue engineering, heart valves, etc.) have been developed for implantation into patients. However, when such devices are implanted into the body, the body can react to these in a number of different ways. These reactions can result in an unexpected risk for patients. Therefore, it is important to assess and optimize the biocompatibility of implantable devices. To date, numerous strategies have been investigated to overcome body reactions induced by the implantation of devices. This review focuses on the foreign body response and the approaches that have been taken to overcome this. The biological response following device implantation and the methods for biocompatibility evaluation are summarized. Then the risks of implantable devices and the challenges to overcome these problems are introduced. Specifically, the challenges used to overcome the functional loss of glucose sensors, restenosis after stent implantation, and calcification induced by implantable devices are discussed.

show abstract

Influence of inflammatory cells and serum on the performance of implantable glucose sensors

Cited by 34 publications

References 0 publications

Non-invasive method to detect the changes of glucose concentration in whole blood using photometric technique

Non-invasive method to detect the changes of glucose concentration in whole blood using photometric technique

Timing of Changes in Interstitial and Venous Blood Glucose Measured With a Continuous Subcutaneous Glucose Sensor

A Review of the Biocompatibility of Implantable Devices: Current Challenges to Overcome Foreign Body Response

Contact Info

Product

Resources

About